Peer Exchange
Our Peer Exchange™ program provides a multi-stakeholder perspective on important issues that providers, pharmacists, payers, and patients grapple with as they step into the world of biosimilars.
The panel identifies specific methods regarding the incorporation of biosimilars as treatment options in oncology.
Expert perspective on how to select a specific biosimilar when several might be available for the same reference biologic.
A brief review of how biosimilars might exist alongside novel or newly approved biologics.
Considerations for biosimilars from the standpoint of market access and how potential challenges are addressed.
The panel sheds light on how a biosimilar’s role in a formulary is determined.
Experts review available oncologic biosimilars and address practical concerns for initiating or switching over to biologic therapy.
Practical perspectives on the challenges related to bringing biosimilars to market.
Specific considerations for how the cost of biologics might make them a preferred option for patients.
Shared insight on the evidence backing biosimilars and their cost compared with biologics.
Comprehensive insight regarding the approval process, availability, and efficacy of biosimilars.
